STOCK TITAN

Altamira Therapeutics Ltd - CYTO STOCK NEWS

Welcome to our dedicated news page for Altamira Therapeutics (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Altamira Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Altamira Therapeutics's position in the market.

Rhea-AI Summary
Altamira Therapeutics receives positive conclusion from FDA for Phase 2 clinical trial of AM-125 in vertigo treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.23%
Tags
none
-
Altamira Therapeutics Ltd

Nasdaq:CYTO

CYTO Rankings

CYTO Stock Data

4.10M
2.22M
0.89%
0.34%
24.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Bermuda
Hamilton

About CYTO

altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”